FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%.

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Health Canada approves Novartis' KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence Français News provided by Novartis Pharmaceuticals Canada Inc. Jun 18, 2025, 08:15 ET ...

Novartis AG (NYSE: NVS) Q3 2024 Earnings Conference Call October 29, 2024 9:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry ...

Kisqali obtained FDA approval for a broad indication for HR+/HER2- stage II and III early breast cancer (eBC) at high risk of recurrence, approximately doubling the population eligible for CDK4/6 ...

The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...

This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS Kisqali for early breast cancer, Merck’s MRK Keytruda for malignant ...

Kisqali will be expensive The cost, out-of-pocket, three-year dose of Kisqali will be close to $300,000-$400,000. However, with the expanded approval, scientists say it is more likely that insurance ...

WEDNESDAY, Sept. 18, 2024 (HealthDay News) -- Women with early-stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...